{"id":"NCT00357903","sponsor":"Amgen","briefTitle":"Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials","officialTitle":"Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1997-04","primaryCompletion":"2008-12","completion":"2009-04","firstPosted":"2006-07-28","resultsPosted":"2010-12-06","lastUpdate":"2017-02-09"},"enrollment":639,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Etanercept","otherNames":[]}],"arms":[{"label":"1","type":"OTHER"}],"summary":"This study was designed to provide all adult and pediatric arthritis patients (placebo and etanercept(TNFR:Fc) treated) who have participated in clinical trials with etanercept (TNFR:Fc) the opportunity to receive continued treatment with etanercept (TNFR:Fc). The primary objective of this study is to examine safety parameters.","primaryOutcome":{"measure":"Total Exposure to Etanercept With Gaps","timeFrame":"Up to 10 years","effectByArm":[{"arm":"Adult Participants","deltaMin":4033.07,"sd":null},{"arm":"Pediatric Participants","deltaMin":341.98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["12672185","12794815","12528122","18438876","16732547","11987981","11409115","16541481","11352248","20957659"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":293,"n":581},"commonTop":["Upper respiratory tract infection","Sinusitis","Headache","Bronchitis","Skin infection"]}}